Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Diabetes and Treatments :Insulin Chart

Diabetes and Treatments :Insulin Chart

Ratings: (0)|Views: 42|Likes:
Published by Sumit Roy
The prevalence of diabetes for all age-groups worldwide was estimated to be
2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise
from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men
than women, but there are more women with diabetes than men. The urban population in
developing countries is projected to double between 2000 and 2030. The most important
demographic change to diabetes prevalence across the world appears to be the increase in the
proportion of people 65 years of age.
The prevalence of diabetes for all age-groups worldwide was estimated to be
2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise
from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men
than women, but there are more women with diabetes than men. The urban population in
developing countries is projected to double between 2000 and 2030. The most important
demographic change to diabetes prevalence across the world appears to be the increase in the
proportion of people 65 years of age.

More info:

Categories:Types, Research
Published by: Sumit Roy on Aug 07, 2013
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

05/25/2014

pdf

text

original

 
24
 
www.DitsHlth.o / December 2011 - january 2012 / DIabeTeS HeaLTH
InsulinManufacturerOnset(approximately)Peak(approximately)Duration(approximately)
     R     A     P     I     D     A     C     T     I     N     G
Apidra(insulin glulisine [rDNA origin] injection)
sao-avetis1530 mites0.52.5 hors 5 hors or less
Apidra SoloSTAR(prelled)
sao-avetis1530 mites0.52.5 hors5 hors or less
Apidra Cartridge
sao-avetis1530 mites0.52.5 hors5 hors or less
Humalog Vial(insulin lispro)
li Lill& ompa15–30 mites0.52.5 hors 5 hors or less
Humalog Cartridge
li Lill& ompa1530 mites0.52.5 hors5 hors or less
Humalog Pen(prelled)
li Lill& ompa1530 mites0.52.5 hors5 hors or less
NovoLog Vial(insulin aspart)
novo nordisk1020 mites13 hors35 hors
NovoLog PenFill
novo nordisk1020 mites13 hors35 hors
NovoLog FlexPen(prelled)
novo nordisk1020 mites13 hors35 hors
     S     H     O     R     T     A     C     T     I     N     G
Humulin R (Regular) Vial
 
a
li Lill& ompa3060 mites24 hors58 hors
Novolin R Vial®(Regular human insulin)
novo nordisk30 mitespharmacodamicpeak of 2.5-5 hors8 hors
     I     N     T     E     R     M     E     D     I     A     T     E     A     C     T     I     N     G
Humulin N (NPH) Vial
li Lill& ompa12 hors28 hors1424 hors
Humulin N (NPH) Pen(prelled)
li Lill& ompa12 hors28 hors1424 hors
Novolin N Vial®(NPH human insulin isophane)
novo nordisk1.8 hors412 hors24 hors
ll islis listed are u-100 stregth. ll islis shold be refrigerated at 36°
46° F.a: lso available i u-500 b prescriptio ol.b: Lats ad Levemir release at a relativel costat rate over a 24-hor period.c: Pes i se (ope) shold ot be stored i the refrigerator.
 ApidraHumulin N Pen
Insulins and Insulin Pens
NovoLogHumalogHumaPen MEMOIR 
 
www.DitsHlth.o / December 2011 - january 2012 / DIabeTeS HeaLTH
25
RoomTemperatureStorage Range(59°–86° F)Need to RollBriskly 10+Times?CartridgeSizesPens That FittheCartridges
up to 28 dasnon/n/up to 28 dasnon/n/up to 28 dasno3 mLOptilik®up to 28 dasnon/n/up to 28 dasno3 mLtopeup to 28 das
 
c
non/n/up to 28 dasnon/n/up to 28 dasno3 mLnovoPe 3,novoPe jiorup to 28 das
c
no3 mLn/up to 28 dasnon/n/up to 42 dasbelow 77° Fnon/n/up to 28 dasyesn/n/up to 14 das
c
yesn/n/up to 42 dasbelow 77° Fyesn/n/
AMYlIN MIMETIc
How It Works
Take at mealtime, SyLIn is the rst ad ol amli mimetic for se i patietswith diabetes treated with mealtime isli. SyLIn is a sthetic aalog of hmaamli, a atrall occrrig hormoe that is made i the beta cells of the pacreas,the same cells that make isli. I patiets with tpe 2 diabetes who se isli,ad i patiets with tpe 1 diabetes, beta cells i the pacreas that make bothisli ad amli are either damaged or destroed, resltig i redced secretio of both isli ad amli after meals. mli deciec ca make it harder to cotrolglcose levels after meals; therefore, sig SyLIn helps patiets to sped moretime i their ormal glcemic rage.
SYMLIN
is give at mealtimes ad is idicated for:• Tpe 2 diabetes, as a adct treatmet i patiets who se mealtime isli therapad who have failed to achieve desired glcose cotrol despite optimal isli therap,with or withot a cocrret slfolrea aget ad/or metformi.• Tpe 1 diabetes, as a adct treatmet i patiets who se mealtime islitherap ad who have failed to achieve desired glcose cotrol despite optimalisli therap.
Brand and Generic Names
SyLIn® (pramlitide acetate) iectio
Manuacturers
mli Pharmaceticals, Ic.
Usual Starting DoseType 1 diabetes:
Iitiate at 15 micrograms immediatel prior to major meals. Whe o cliicall sigicatausea has occurred for 3 das, titrate at 15-microgram itervals to maiteace dose of 30 or 60 micrograms as tolerated. Whe startig SyLIn, reduce rapid-actig or short-actig isuli, icludig xed-mix isuli such as 70/30, used before meals b 50 percet.ll isuli chages should be directed b health professioals.
Type 2 diabetes:
Iitiate at 60 micrograms immediatel prior to maor meals. Whe o cliicallsigicat asea has occrred for 3-7 das, titrate to maiteace dose of 120micrograms as tolerated. Whe startig SyLIn, redce rapid-actig or short-actigisli, icldig xed-mix isli sch as 70/30, sed before meals b 50 percet.ll isli chages shold be directed b health professioals.
Maximum Daily DoseType 1 diabetes:
Tpical maiteace dose of SyLIn i tpe 1 diabetes is 30 to 60 micrograms astolerated. fter reachig a appropriate maiteace dose of SyLIn, chages toisuli doses ma be eeded to better cotrol blood sugar. ll isuli chages shouldbe directed b health professioals.
Type 2 diabetes:
Tpical maiteace dose of SyLIn i tpe 2 diabetes is 120 micrograms as tolerated.fter reachig a appropriate maiteace dose of SyLIn, chages to isuli dosesma be eeded to better cotrol blood sugar. ll isuli chages should be directed bhealth professioals.
Adverse Efects
Other adverse evets commol observed with SyLIn whe co-admiistered with isuliwere mostl gastroitestial i ature, icludig ausea, which was the most frequetlreported adverse evet. The icidece of ausea was higher at the begiig of SyLIntreatmet ad decreased with time i most patiets. The icidece ad severit of auseaare reduced whe SyLIn is graduall icreased to the recommeded doses.
Customer upport: li Lilly & Co. (800) 545-5979ovo ordisk (800) 727-6500sanof-aventis (800) 633-1610
Printer-friendly charts are available at www.DiabetesHealth.com/charts
 
26
 
www.DitsHlth.o / December 2011 - january 2012 / DIabeTeS HeaLTH
InsulinManufacturerOnset(approximately)Peak(approximately)
     L     O     N     G     A     C     T     I     N     G
Lantus Vial(insulin glargine [rDNA origin] injection)
sao-avetis1.5 hosnoe
 b
Lantus Cartridge
sao-avetis1.5 hosnoe
 b
Lantus SoloSTAR®(prelled)
sao-avetis1.5 hosnoe
 
Levemir Vial(insulin detemir [rDNA origin] injection)
novo nodisk1.6 hosrelativelat
Levemir FlexPen(insulin detemir [rDNA origin] injection)
novo nodisk1.6 hosrelativelat
     I     N     T     E     R     M     E     D     I     A     T     E     /     R     A     P     I     D     A     C     T     I     N     G
Humalog Mix 75/25 Vial
li Lill& ompa1530 mites0.52.5 hos
Humalog Mix 75/25 Pen (prelled)
li Lill& ompa1530 mites0.52.5 hos
NovoLog Mix 70/30 Vial®
(70% insulin aspart protamine suspension/30% aspart)
novo nodisk1020 mites2.4 hos
NovoLog Mix 70/30 FlexPen®
novo nodisk1020 mites2.4 hos
     I     N     T     E     R     M     E     D     I     A     T     E     /     S     H     O     R     T     A     C     T     I     N     G
Humulin 70/30 Vial (70% NPH/30% Regular)
li Lill& ompa3060 mites0.55 hos
Humulin 70/30 Pen (prelled)
li Lill& ompa3060 mites24 hos
Novolin 70/30 Vial® (70% NPH/3 0% Regular)
novo nodisk30 mites212 hos
Humulin 70/30 PenLantus
Insulins and Insulin Pens
ll islis listed ae u-100 stegth. ll islis shold be efigeated at 36°
46° F.a: lso available i u-500 b pesciptio ol.b: Lats ad Levemi elease at a elativel costat ate ove a 24-ho peiod.c: Pes i se (ope) shold ot be stoed i the efigeato.
LantusLevemir 

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->